Extended Data Fig. 1: Intratumoural IL33 expression in human tumours.
From: IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer
a, b, Correlation of intratumoural IL33 mRNA expression to TLS transcriptional signatures (TLS signature: 14, 27, 38), and LTB mRNA expression in human PDAC cohorts (top, Memorial Sloan Kettering Cancer Center (MSK) cohort; bottom, International Cancer Genome Consortium (ICGC) cohort) and human tumours from the Cancer Genome Atlas (b). c, IL-33 immunohistochemistry in human PDACs with TLSs. Dotted red lines = putative TLS. d, Immunofluorescence images of TLSs in human PDACs. e, f, Serum IL-33 in rIL-33-treated PDAC mice (e) and in human PDAC patients (f). g, Correlation of IL-33-activated human ILC2 transcriptional signature to TLS signatures (TLS signatures: 14, 27, 38) in human tumours from the Cancer Genome Atlas. n = number of tumours (a, b, g), mice (e) or patients (f). Data collected at 4 weeks (e) after tumour implantation, pooled from 2 independent experiments with n ≥ 3 mice per group with consistent results. P values by two-sided Pearson’s correlation (a, b, g).
